上海信公轶禾企业管理咨询有限公司 关于 东富龙科技集团股份有限公司 2021 年限制性股票激励计划 预留授予部分第三期归属相关事项 之 独立财务顾问报告 独立财务顾问： 二〇二四年十二月 2 上海信公轶禾企业管理咨询有限公司 独立财务顾问报告 第一章 声 明 上海信公轶禾企业管理咨询有限公司接受委托，担任东富龙科技集团股份有 限公司（以下简称"东富龙"或"上市公司"、"公司"）2021 年限制性股票激励计划 （以下简称"本激励计划"）的独立财务顾问（以下简称"本独立财务顾问"），并制 作本独立财务顾问报告。本独立财务顾问报告是根据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司股权激励管理办法》《深圳证券交易所创业 板股票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业 务办理》等法律、法规和规范性文件的有关规定，在东富龙提供有关资料的基础 上，发表独立财务顾问意见，以供东富龙全体股东及有关各方参考。 一、本独立财务顾问报告所依据的文件、材料由东富龙提供，东富龙已向本 独立财务顾问保证：其所提供的有关本激励计划的相关信息真实、准确和完整， 保证该等信息不存在虚假记载、误导性陈述 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥1,198,678,191.49, a decrease of 12.78% compared to the same period last year[4] - Net profit attributable to shareholders was ¥38,775,095.60, reflecting a significant decline of 75.35% year-over-year[4] - The net profit after deducting non-recurring gains and losses was ¥32,923,617.15, down 77.52% from the previous year[4] - The basic earnings per share decreased to ¥0.0505, a drop of 75.76% compared to the same period last year[4] - The total profit for Q3 2024 was ¥180,345,365.21, a significant decrease from ¥705,425,423.58 in Q3 2023, reflecting a decline of approximately 74.5%[20] - Net profit for Q3 2024 was ¥155,303,814.59, down from ¥626,119,934.47 in the same period last year, representing a decrease of about 75.2%[20] - The total comprehensive income for Q3 2024 was ¥154,796,788.67, compared to ¥627,281,499.77 in Q3 2023, a decrease of approximately 75.3%[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥13,082,049,184.09, an increase of 1.42% from the end of the previous year[4] - The total assets increased to CNY 13,082,049,184.09 from CNY 12,898,331,017.19, indicating growth in the asset base[18] - The total liabilities rose to CNY 5,028,893,132.24 from CNY 4,788,877,438.21, suggesting increased leverage[18] Cash Flow and Liquidity - The company's cash flow from operating activities showed a significant increase of 224.84%, amounting to ¥428,458,154.47 year-to-date[4] - Operating cash flow for Q3 2024 was ¥428,458,154.47, a recovery from a negative cash flow of ¥343,207,266.30 in Q3 2023[22] - The company reported a net cash increase of ¥158,586,588.00 in Q3 2024, contrasting with a significant decrease of ¥1,432,112,241.50 in Q3 2023[23] - The company's cash and cash equivalents increased to CNY 2,477,211,666.64 from CNY 2,288,215,940.13, indicating improved liquidity[15] - The company’s cash and cash equivalents at the end of Q3 2024 totaled ¥2,430,864,918.29, down from ¥3,274,691,977.80 at the end of Q3 2023[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 33,038, with the largest shareholder, Zheng Xiaodong, holding 34.08% of shares, equating to 260,959,008 shares[8] - The company completed a share repurchase of 4,980,001 shares, representing 0.65% of the total share capital, with a total transaction amount of RMB 63,943,727.13[13] - The cash dividend for the 2023 annual equity distribution is RMB 2.391867 per 10 shares, totaling RMB 182,306,270.32 distributed to shareholders[12] - Zheng Xiaodong's restricted shares increased to 195,719,256 shares after an addition of 1,065,000 shares during the reporting period[10] - The company has a total of 762,192,339 shares for the cash dividend distribution after excluding repurchased shares[12] - The top ten shareholders include significant stakes from Zheng Kexing (16.41%) and several investment funds, indicating a diverse shareholder base[8] Operational Efficiency - Total operating costs amounted to CNY 3,294,838,490.42, down from CNY 3,554,970,138.12, reflecting a cost reduction strategy[19] - Accounts receivable rose to CNY 1,727,071,659.25, up from CNY 1,517,357,323.56, suggesting potential challenges in collections[15] - Inventory decreased to CNY 3,519,174,266.50 from CNY 3,610,799,943.04, reflecting better inventory management[15] - Research and development expenses were CNY 246,695,660.80, slightly down from CNY 269,639,317.06, indicating a focus on cost control in innovation[19] Future Outlook - The company plans to expand its market presence and invest in new technologies to drive future growth[19] - The company has not disclosed any new product developments or market expansion strategies in this report[14]

中信证券股份有限公司 关于东富龙科技集团股份有限公司 2024年半年度跟踪报告 | 事项 | 存在的问题 保荐人查阅了公司信息披露文件，投资者关 | 采取的措施 | | --- | --- | --- | | | 系登记表，深圳证券交易所互动易网站披露 | | | 1.信息披 | 信息，重大信息的传递披露流程文件，内幕 | | | 露 | 信息管理和知情人登记管理情况，信息披露 | 不适用 | | | 管理制度，检索公司舆情报道，对公司董事 | | | | 会秘书、财务总监进行访谈，未发现公司在 | | | | 信息披露方面存在重大问题。 | | | 2.公司内 | 保荐人查阅了公司章程及内部制度文件，对 | | | 部制度的 | 公司董事会秘书、财务总监进行访谈，未发 | | | 建立和执 | 现公司在公司内部制度的建立和执行方面存 | 不适用 | | 行 | 在重大问题。 | | | | 保荐人查阅了公司最新章程、三会议事规则 | | | 3．"三会" | 及会议材料、信息披露文件，对公司董事会 | 不适用 | | 运作 | 秘书、财务总监进行访谈，未发现公司在"三 | | | | 会"运作方面存在重大问 ...

证券代码：300171 证券简称：东富龙 东富龙科技集团股份有限公司投资者关系活动记录表 编号：2024-003 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 ■其他 电话会议 | | 参与单位名称 | 电话通讯方式与会名单请见附件 | | 及人员姓名 | | | 时间 | 2024 年 8 月 30 日 8：30—9：30 | | 地点 | 电话会议 | | 上市公司接待 | 财务总监：陆德华 | | 人员姓名 | 副总经理兼董事会秘书：王艳 | | | 投资总监：张盟 1、公司 2024 年半年度经营情况介绍。 | | | 年半年度公司实现营业收入 亿元（国内收入 答：2024 22.91 17.98 亿元，占比 78.49%；国际收入 亿元，占比 21.51%），较上年同 4.93 | | | 期下降 22.36%；归属于上市公司股东的净利润 1.14 亿元，较上年同 | | | 期下降 73.25%；归属于上市公司扣非后净利润 0.99 亿元，较上年同 | | ...

Financial Performance - Revenue for the reporting period was RMB 2.29 billion, a decrease of 22.36% compared to the same period last year[15] - Net profit attributable to shareholders of the listed company was RMB 113.97 million, a decrease of 73.25% year-on-year[15] - Net cash flow from operating activities was RMB 191.97 million, a significant increase of 161.40% compared to the same period last year[15] - Basic earnings per share (EPS) were RMB 0.1498, a decrease of 73.44% year-on-year[15] - Weighted average return on equity (ROE) was 1.44%, down 4.13 percentage points from the same period last year[15] - Total assets at the end of the reporting period were RMB 12.91 billion, a slight increase of 0.11% compared to the end of the previous year[15] - The company achieved revenue of approximately 2.291 billion yuan in the first half of 2024, a decrease of 22.36% compared to the same period in 2023[39] - Net profit attributable to the parent company in the first half of 2024 was approximately 114 million yuan, a decrease of 73.25% year-on-year[39] - Revenue decreased by 22.36% to 2,290,913,300.80 yuan, primarily due to slower fixed asset investment by downstream customers[42] - Net cash flow from operating activities increased by 161.40% to 191,968,271.79 yuan, driven by higher cash receipts from sales and reduced payments for goods and taxes[42] - R&D investment decreased by 6.24% to 153,918,552.97 yuan, mainly due to stricter project management and reduced material costs[42] - The Formulation Division's revenue decreased by 20.36% to 1,259,013,745.93 yuan, with a gross margin of 31.41%[43] - The Bioprocess Division's revenue decreased by 32.73% to 538,395,099.18 yuan, with a gross margin of 29.86%[43] - Domestic revenue decreased by 24.11% to 1,798,061,366.65 yuan, while international revenue decreased by 15.21% to 492,851,934.15 yuan[43] - Investment income was 9,902,341.40 yuan, accounting for 6.98% of total profit, mainly from interest income and long-term equity investment gains[44] - Accounts receivable increased by 1.09% to 1,658,758,801.81 yuan, due to higher new receivables from revenue recognition compared to collections[46] - Inventory decreased by 1.10% to 3,472,349,676.25 yuan, driven by improved order delivery management and reduced obsolete stock[46] - Fixed assets increased by 1.07% to 955,500,284.08 yuan, mainly due to the transfer of the second phase of the pharmaceutical equipment manufacturing base project[46] - The company's total investment in the reporting period was RMB 246,737,130.73, a 2.59% increase compared to the same period last year[49] - The company's financial assets at fair value totaled RMB 819,794,548.08, with a fair value change gain of RMB 8,675,877.99 during the period[47] - Restricted monetary funds at the end of the reporting period amounted to RMB 34,155,364.53, primarily due to performance bonds, litigation frozen funds, and restricted overseas funds[48] - The company has cumulatively invested RMB 300,992.25 million in raised funds, with RMB 23,496.12 million invested during the reporting period[49] - The company invested RMB 5,597.90 million in the biopharmaceutical equipment industry trial center project using funds raised from specific object issuance[49] - The company invested RMB 12,124.29 million in the Jiangsu biopharmaceutical equipment industrialization base project using funds raised from specific object issuance[49] - The company invested RMB 5,773.93 million in the Zhejiang Dongfulong Biotechnology Co., Ltd. life science industrialization base project using funds raised from specific object issuance[50] - The aseptic freeze-drying pharmaceutical equipment system integration industrialization project has achieved a cumulative investment of RMB 16,037.8 million, with an investment progress of 54.18%[51] - The biopharmaceutical equipment industry trial center project has achieved a cumulative investment of RMB 12,990.55 million, with an investment progress of 24.51%[51] - The Jiangsu biopharmaceutical equipment industrialization base project has achieved a cumulative investment of RMB 28,916.33 million, with an investment progress of 46.64%[51] - Acquired Shanghai Dianfan Medical Technology Co., Ltd. and increased capital by 3,000 million RMB, holding 100% ownership[52] - Acquired Shanghai Ruipai Machinery Co., Ltd. and increased capital by 4,895 million RMB, holding 100% ownership[52] - Purchased a building in Yigu·Modern Business Park (Phase II) for 2,659.72 million RMB, holding 100% ownership[52] - Purchased a building in Wuhan Jiulong Bio-Industry Base Bio-Pharmaceutical Industrial Park Accelerator Phase II for 1,638.6 million RMB, holding 99.68% ownership[52] - Increased capital in Shanghai Dongfulong Intelligent Control Technology Co., Ltd. by 9,900 million RMB, holding 100% ownership[52] - Established Shanghai Dongfulong Medical Technology Industry Development Co., Ltd. with an investment of 50,000 million RMB, holding 100% ownership[52] - Acquired 40% equity of Shanghai Yufa Pharmaceutical Co., Ltd. for 3,600 million RMB, holding 100% ownership[52] - Increased capital in Shanghai Dongfulong Pharmaceutical Equipment Manufacturing Co., Ltd. by 37,000 million RMB, holding 100% ownership[52] - Total over-raised funds used amounted to 143,412.28 million RMB, with actual usage of 143,407.08 million RMB[57] - The pharmaceutical equipment container manufacturing base project (Phase I) did not meet expected profits due to relatively low gross margins in basic manufacturing[53] - Company used 36.1 million yuan of over-raised funds to increase its stake in Shanghai Chenghuan Light Industry Machinery Co., Ltd. to 51%[58] - Company used 22.5 million yuan of over-raised funds to acquire 15% equity in Shanghai Dongfulong Dehui Air Conditioning Equipment Co., Ltd., making it a wholly-owned subsidiary[58] - Company plans to use 370 million yuan of over-raised funds to invest in the construction of a biopharmaceutical system equipment industrialization project through its wholly-owned subsidiary Shanghai Dongfulong Pharmaceutical Equipment Manufacturing Co., Ltd.[58] - Company changed the implementation location of the "Aseptic Freeze-drying Pharmaceutical Equipment System Integration Industrialization Project" from No. 1509, Duhui Road, Minhang District, Shanghai to No. 139, Duhui Road, Minhang District, Shanghai[58] - Company used 17.51 million yuan of raised funds to replace self-raised funds previously invested in the pharmaceutical equipment container manufacturing base construction project (Phase I)[58] - Company used 173.81 million yuan of raised funds to replace self-raised funds previously invested in the 2022 specific object issuance project[58] - Company completed the replacement of 347.61 million yuan of raised funds for pre-paid issuance fees and self-raised funds invested in the 2022 specific object issuance project[58] - The pharmaceutical equipment container manufacturing base construction project (Phase I) had a net surplus of 45.93 million yuan after deducting unpaid quality assurance funds and balances[58] - The company saved part of the planned equipment purchase funds by using its own funds to purchase equipment in advance, resulting in a net surplus of 135.29 million yuan for the "Aseptic Freeze-Drying Pharmaceutical Integration Project"[59] - The "Aseptic Freeze-Drying Pharmaceutical Integration Project" had an actual investment of 160.71 million yuan, accounting for 54.29% of the committed investment amount[59] - The company transferred 165.31 million yuan of surplus funds from the "Aseptic Freeze-Drying Pharmaceutical Integration Project" to the over-raised funds account for management and use in main business development and related industrial investments[59] - The company used 26 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.19%/3.2981%[60] - The company used 24 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.20%/2.4324%[60] - The company used 26 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.19%/2.4433%[60] - The company used 24 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.20%/2.4218%[60] - The company used 26 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.29%/2.4315%[60] - The company used 43 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.30%/2.7304%[60] - The company used 47 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.29%/2.7402%[60] - The company purchased a structured deposit of 20 million yuan from Ningbo Bank with an expected annualized return rate of 1.0000%-3.0000%, earning a profit of 299,178.08 yuan[61] - The company purchased another structured deposit of 30 million yuan from Ningbo Bank with an expected annualized return rate of 1.5%-2.8%[61] - The company transferred 4.375 million shares at a price of 35 million yuan, which was returned to the over-raised funds account[61] - The total amount of entrusted wealth management during the reporting period was 653.6561 million yuan, with 526.1561 million yuan not yet due[63] - Shanghai Hanou subsidiary achieved a net profit of 21.7776 million yuan, contributing significantly to the company's overall performance[67] - Dongfulong Medical subsidiary reported a net loss of 17.2898 million yuan, impacting the company's overall profitability[67] - The company faces risks from intense industry competition and is focusing on upgrading manufacturing and expanding international markets to mitigate these risks[69] - Economic cycle and market demand fluctuations pose risks, and the company is maintaining flexible production and supply chains to adapt to market changes[69] - The company is actively pursuing external mergers and acquisitions to accelerate growth in bioprocessing and food equipment engineering, which may increase management risks[69] - Internal management risks are heightened due to industry transformation, and the company is improving organizational models and management levels to meet market demands[69] - The company's actual controller, Zheng Xiaodong, increased his shareholding by 1,770,000 shares, accounting for 0.23% of the total shares, with a total investment of 30,025,652 yuan (excluding transaction fees)[74] - The company implemented a 2023 equity distribution plan, distributing 2.391867 yuan per 10 shares, totaling 182,306,270.32 yuan (including tax)[74] - The company completed a share repurchase of 4,980,001 shares, accounting for 0.6503% of the total shares, with a total repurchase amount of 63,943,727.13 yuan (excluding transaction fees)[74] - The company's 2023 annual general meeting had a 61.44% investor participation rate[76] - The company is focusing on internationalization, digitalization, and systemization, with continuous investment in R&D and technological cooperation in the biopharmaceutical industry[74] - The company is strengthening its management structure and internal control systems to improve operational standards[74] - The company is actively engaging with investors through hotlines and interactive platforms, and held an annual performance briefing after the 2023 annual report[75] - The company is addressing exchange rate risks by using financial tools, optimizing settlement methods, and enhancing the recruitment and training of financial professionals[70] - The company is mitigating investment impairment risks by strengthening post-investment management and strategic alignment with acquired companies[70] - The company is enhancing human resource management by building a learning organization and training platforms to support employee growth and value creation[70] - The company adjusted the number of incentive recipients for the 2021 restricted stock incentive plan from 383 to 368, with the total number of restricted shares remaining at 20 million[78] - The company granted 300,000 restricted shares to 19 incentive recipients at a price of 9.47 yuan per share on December 3, 2021, with 1.915 million reserved shares becoming invalid[78] - In the first vesting period of the 2021 restricted stock incentive plan, 7.078 million shares were vested by 352 recipients, with the shares becoming tradable on May 20, 2022[78] - In the first vesting period of the reserved portion of the 2021 restricted stock incentive plan, 108,000 shares were vested by 17 recipients, with the shares becoming tradable on January 20, 2023[79] - In the second vesting period of the 2021 restricted stock incentive plan, 5.1795 million shares were vested by 336 recipients, with the shares becoming tradable on May 29, 2023[80] - In the second vesting period of the reserved portion of the 2021 restricted stock incentive plan, 72,000 shares were vested by 15 recipients, with the shares becoming tradable on December 22, 2023[80] - In the third vesting period of the 2021 restricted stock incentive plan, 4.9875 million shares were vested by 311 recipients, with the shares becoming tradable on May 23, 2024[80] - The company has provided over 10,000 pharmaceutical equipment and systems to nearly 3,000 well-known pharmaceutical companies in more than 50 countries and regions globally[82] - The company has held investor meetings, conference calls, and roadshows, receiving recognition from the capital market and investor relations community[84] - Since its listing in 2011, the company has conducted annual equity distributions, providing stable returns to investors[84] - The company has established a comprehensive quality management system based on ISO9001, integrating ICHQ9 quality risk management and GMP standards to enhance customer satisfaction[86] - Products are designed for the pharmaceutical, food, and medical industries, utilizing 304 or 316L stainless steel materials and advanced SCADA systems for automation[86] - The company invests millions annually in environmental protection and energy conservation, including the use of solar power to reduce electricity consumption[88] - A robust EHS (Environment, Health, and Safety) system is in place, with regular environmental inspections and emergency response drills[87] - The company actively participates in social welfare activities, including educational support, poverty alleviation, and disaster relief efforts[88] - Employee benefits include comprehensive insurance, housing, meals, and annual health check-ups, with additional support for families in need[85] - The company adheres to strict labor laws, ensuring all employees are paid above the Shanghai minimum wage and receive annual performance-based bonuses[85] - Supplier relationships are managed through annual and strategic cooperation agreements, with a focus on quality and mutual development[86] - The company has implemented green manufacturing practices, such as using environmentally friendly refrigerants and energy-efficient compressors[86] - The company's commitment to sustainability includes regular updates to environmental policies and active participation in community environmental initiatives[87] - The company's total shares increased from 760,774,540 to 765,762,040 due to the third vesting period of the 2021 restricted stock incentive plan, with 4,987,500 shares issued[104] - The company's actual controller, Zheng Xiaodong, increased his holdings by 1,420,000 shares during the reporting period, with 1,065,000 shares locked under the 75% lock-up rule[105] - The company plans to repurchase shares worth between 50 million yuan and 100 million yuan, with an estimated repurchase of 2.14 million to 4.28 million shares, accounting for 0.28% to 0.56% of the total shares[105] - The company leased properties in Hangzhou, Shanghai, and Jinshan, including office spaces and land use rights, but none of these leases contributed more than 10% of the company's total profit[100] - The company's restricted shares increased by 1,656,750 shares, bringing the total restricted shares to 203,170,685, accounting for 26.53% of the total shares[104] - The company's unrestricted shares increased by 3,330,750 shares, bringing the total unrestricted shares to 562,591,355, accounting for 73.47% of the total shares[104] - The company repurchased 4,980,001 shares, accounting for 0.6503% of the total shares, with a total repurchase amount of RMB 63,943,727.13[106] - The repurchase price ceiling was adjusted from RMB 23.35 per share to RMB 23.11 per share due to the 2023 annual equity distribution[106] - The company's total shares increased from 760,774,540 to 765,762,040 after the listing of 4,987,500 restricted shares from the 2021 restricted stock incentive plan[106] - The total number of restricted shares held by executives increased from 201,513,935 to 203,170,685[108] - The largest shareholder, Zheng Xiaodong, holds 34.08% of the shares, with 195,719,256 shares under lock-up[109] - The second-largest shareholder, Zheng Keqing, holds 16.41% of the shares, with all 125,667,408 shares being freely tradable[109] - The top 10 shareholders include Shanghai Biopharmaceutical Industry Equity Investment Fund and SDIC Innovation Investment Management, each holding 3.17% of the shares[109] - The top 10 shareholders also include Shanghai Junhe Licheng Investment Management Center, holding 1.90% of the shares[109] - The top 10 shareholders include Gaoyi Asset Management Partnership, holding 1.88% of the shares[111] - The top 10 shareholders include Hong Kong Securities Clearing Company, holding 1.83% of the shares[111] - The company's monetary funds at the end of the

第六届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）第六届董事会第十一次 会议于 2024 年 8 月 18 日以电话、书面方式通知各位董事，会议于 2024 年 8 月 29 日（星期四）在公司（上海市闵行区都会路 1509 号）305 会议室以现场加通 讯的会议方式召开。本次董事会会议应出席董事 9 名，实际出席会议董事 9 名（独 立董事邵俊先生因公出差未亲自出席会议，授权委托独立董事张爱民先生代为出 席并行使表决权）。会议由董事长郑效东先生主持。公司监事及高级管理人员列 席本次会议。会议符合《公司法》及《公司章程》的有关规定。会议经认真审议， 通过如下议案： 证券代码：300171 证券简称：东富龙 公告编号：2024-035 东富龙科技集团股份有限公司 一、审议通过《2024 年半年度报告及摘要》 董事会认为，公司《2024 年半年度报告》全文及《2024 年半年度报告摘要》 符合法律、行政法规、中国证券监督管理委员会和深圳证券交易所的相关规定， 内容真实、准确、完整，不存在 ...

东富龙科技集团股份有限公司（以下简称"公司"）第六届监事会第九次会 议于 2024 年 8 月 18 日以电话、书面方式通知各位监事，会议于 2024 年 8 月 29 日（星期四）在公司（上海市闵行区都会路 1509 号）305 会议室以现场会议方 式召开。本次监事会会议应出席的监事 3 名，实际出席会议的监事 3 名。本次会 议由监事会主席杨东生先生主持。公司董事会秘书列席本次会议。会议的召开符 合《公司法》及《公司章程》的有关规定。会议经认真审议，通过如下议案： 一、审议通过《公司 2024 年半年度报告及摘要》 监事会认为：董事会编制和审核公司 2024 年半年度报告全文及摘要的程序 符合法律、行政法规、中国证券监督管理委员会和深圳证券交易所的相关规定， 报告内容真实、准确、完整地反映了本公司实际的情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 证券代码：300171 证券简称：东富龙 公告编号：2024-036 东富龙科技集团股份有限公司 第六届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 赞成票，3 票，占出席会议 ...

| | 浙江创新生物有限公 | 董事担任董事的 | 应收、合同资产、 | 145.87 | 9.98 | | 57.79 | 98.06 | 销售商品 | 经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 司 | 公司 | 合同负债 | | | | | | | | | | 康希诺生物股份公司 | 董事担任董事的 | 应收、合同资产、 | 31.60 | 5.87 | | 26.65 | 10.82 | 销售商品 | 经营性往来 | | | | 公司 | 合同负债 | | | | | | | | | | 上海雷昶科技有限公 | 董事担任董事的 | 应付、预付账款 | 134.34 | - | | 40.00 | 94.34 | 采购商品 | 经营性往来 | | | 司 | 公司 | | | | | | | | | | | 百剂博递医药科技 | 董事担任董事的 | 应收、合同资产、 | 13.80 | | | | 13.80 | 房屋出租 | 经营性往来 | | | （上海）有限公司 | 公司 | 合同负 ...

证券代码：300171 证券简称：东富龙 公告编号：2024-038 东富龙科技集团股份有限公司 关于公司 2024 年半年度计提资产减值准备及资产核销的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 一、本次计提资产减值准备 （一）情况概述 1、本次计提资产减值准备的原因 依照《企业会计准则》及东富龙科技集团股份有限公司（以下简称"公司"） 会计政策的相关规定，公司对合并范围内截止 2024 年半年度末的各类存货、应 收账款、合同资产、其他应收款、固定资产、在建工程、无形资产等资产进行全 面清查，对各类存货的可变现净值、应收款项回收的可能性、固定资产、长期股 权投资、在建工程、无形资产、商誉等资产的可变现性进行充分的评估和分析， 认为上述资产中部分资产存在一定的减值迹象，本着谨慎性原则，对可能发生资 产减值损失和信用减值损失的资产计提减值准备。 2、本次计提资产减值准备的资产范围和总金额 公司及下属子公司对 2024 年半年度末存在可能发生减值迹象的资产进行全 面清查和资产减值测试后，计提 2024 年半年度各项资产减值准备共计人民币 70,258, ...

东富龙科技集团股份有限公司 2024年半年度 募集资金存放与使用情况的专项报告 东富龙科技集团股份有限公司 2024 年半年度募集资金存放与实际使用情况的专项报告 | 项目 | 金额 | | --- | --- | | 募集资金净额 | 1,570,528,161.60 | | 减：以前年度已使用募集资金金额 | 1,730,322,891.92 | | 减：2024 年半年度使用募集资金金额 | - | | 加：累计募集资金利息收入扣除手续费净额 | 232,819,721.41 | | 其中：本年度募集资金利息收入减除手续费 | 2,038.63 | | 加：累计购买理财产品的收益 | 109,190,430.83 | | 其中：本年度购买理财产品的收益 | - | | 尚未使用的募集资金余额（注） | 182,215,421.92 | 注：截止 2024 年 6 月 30 日，尚未使用的募集资金余额 182,215,421.92 元， 全部存放于募集资金专户。截至 2024 年 6 月 30 日，超募资金（不含利息）已全 部使用完毕，尚未使用的募集资金余额均为累计的利息收入和理财收益。 根据中国证券监督 ...